Keywords
Tissue Inhibitor of Metalloproteinases
Connective Tissue Dysplasia
Abstract
The article presents the results of a study of the activity of Matrix Metalloproteinase Type 9 (MMP‑9) and Tissue Inhibitor of Matrix Metalloproteinases type 1 (TIMP‑1) in postmenopausal patients with Undifferentiated Connective Tissue Dysplasia (UCTD) and diseases of the cardiovascular system. The aim of the study was to evaluate serum levels of Matrix Metalloproteinase Type 9 and Tissue Inhibitor of Matrix Metalloproteinases Type 1, to identify associations with diseases of the cardiovascular system and features of therapy in postmenopausal patients with UCTD. Materials and methods. A cross-sectional study enrolled 84 patients in late postmenopause with arterial hypertension (AH). UCTD was identified according to the recommendations of the Russian Medical Scientific Society of Internists. Group 1 included 22 patients with AH and UCTD, group 2 consisted of 62 patients with AH without UCTD. Serum levels of MMP‑9 and TIMP‑1 were assessed by solid-phase heterogeneous Enzyme Immunoassay (ELISA) using RayBio test systems. Results. The frequency of the main associated clinical conditions and the structure of AH in the studied groups did not differ significantly. There were no significant differences in the structure of antihypertensive therapy, antiplatelet and antihypertensive therapy, no significant differences between the groups were found. There were no significant differences in the levels of collagen degradation markers in patients with AH+UCTD and AH subjects without UCTD. In patients with Coronary Heart Disease (CHD), there was a significant increase in the level of MMP‑9 and an increase in the ratio of MMP‑9/TIMP‑1 (p = 0.02). One-way Analysis of Variance (ANOVA) revealed a significant MMP‑9 serum level decrease in patients with coronary artery disease receiving ARB-II 1 type.
For citationShambatov MA, Izmozherova NV, Popov AA, Bazarnyj VV, Polushina LG, Kopenkin MA. The level of type 9 matrix metalloproteinase and tissue inhibitor of matrix metalloproteinases‑1 in postmenopausal patients with cardiovascular сonditions. Bulletin of USMU. 2023;(2):8–20. (In Russ.). EDN: https://elibrary.ru/SSEMBJ.
References
Preventing and Experiencing Ischemic Heart Disease as a Woman: State of the Science: A Scientific Statement From the American Heart Association / J. C. McSweeney, A. G. Rosenfeld, W. M. Abel [et al.] // Circulation. 2016. Vol. 133, Iss. 13. P. 1302–1331. DOI: https://doi.org/10.1161/CIR.0000000000000381.
Попов А. А., Изможерова Н. В., Обоскалова Т. А. Одномоментное исследование мультиморбидной патологии у женщин с дефицитом эстрогенов // Уральский медицинский журнал. 2020. № 6 (189). С. 69–76. DOI: https://doi.org/10.25694/URMJ.2020.06.16.
Наследственные нарушения соединительной ткани в кардиологии. Диагностика и лечение. Российские рекомендации (I пересмотр) / Э. Г. Малев, Г. А. Березовская, Н. Н. Парфенова [и др.] // Российский кардиологический журнал. 2013. Т. 18, № 1. С. 1–32. URL: https://clck.ru/34uDfN (дата обращения: 26.06.2023).
Торшин И. Ю., Громова О. А. Дисплазия соединительной ткани, клеточная биология и молекулярные механизмы воздействия магния // Русский медицинский журнал. 2008. № 4. С. 230–238. URL: https://clck.ru/34uDbF (дата обращения: 26.06.2023).
Бен Салха М., Репина Н. Б. Клиническая диагностика недифференцированной дисплазии соединительной ткани // Российский медико-биологический вестник имени академика И. П. Павлова. 2016. Т. 24, № 4. С. 164–172. DOI: https://doi.org/10.23888/PAVLOVJ20164164-172.
Matrix metalloproteinase‑9: Many shades of function in cardiovascular disease / A. Yabluchanskiy, Y. Ma, R. P. Iyer [et al.] // Physiology. 2013. Vol. 28, Iss. 6. P. 391–403. URL: https://clck.ru/34uY6u (дата обращения: 26.06.2023).
Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure / E. M. Wilson, H. R. Gunasinghe, M. L. Coker [et al.] // Journal of Cardiac Failure. 2002. Vol. 8, Iss. 6. P. 390–398. DOI: https://doi.org/10.1054/jcaf.2002.129659.
Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: Relationship to cardiac function / W. Kosmala, R. Plaksej, M. Przewlocka-Kosmala [et al.] // International Journal of Obesity. 2008. Vol. 32, Iss. 5. P. 763–771. DOI: https://doi.org/10.1038/sj.ijo.0803794.
Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease / S. H. Ahmed, L. L. Clark, W. R. Pennington [et al.] // Circulation. 2006. Vol. 113, Iss. 17. P. 2089–2096. URL: https://clck.ru/34uY8S (дата обращения: 26.06.2023).
Rybakowski J. K. Matrix Metalloproteinase‑9 (MMP9) — A Mediating Enzyme in Cardiovascular Disease, Cancer, and Neuropsychiatric Disorders // Cardiovasc Psychiatry Neurol. 2009. Vol. 2009. P. 1–7. DOI: https://doi.org/10.1155/2009/904836.
Сравнительный анализ данных проспективного исследования биохимических параметров сыворотки крови у больных ишемической болезнью сердца с наличием и отсутствием сахарного диабета 2 типа / Т. И. Петелина, Н. А. Мусихина, Л. И. Гапон [и др.] // Уральский медицинский журнал. 2018. № 7 (162). С. 72–78. DOI: https://doi.org/10.25694/URMJ.2018.04.128.
Клинико-анамнестические и биологические претенденты на участие в механизмах формирования пролапса гениталий у женщин / Н. М. Миляева, В. В. Ковалев, Е. А. Бортник [и др.] // Уральский медицинский журнал. 2021. Т. 20, № 1. С. 82–88. DOI: https://doi.org/10.52420/2071-5943-2021-20-1-82-88.
Недифференцированные дисплазии соединительной ткани (проект клинических рекомендаций) / Е. В. Акатова, В. В. Аникин, В. Г. Арсентьев [и др.] // Терапия. 2019. Т. 5, № 7 (33). С. 9–42. DOI: https://doi.org/10.18565/therapy.2019.7.9-42.
Kim Y. H., Kwon H. J., Kim D. S. Matrix metalloproteinase 9 (MMP‑9)-dependent processing of βig-h3 protein regulates cell migration, invasion, and adhesion // Journal of Biological Chemistry. 2012. Vol. 287, Iss. 46. P. 38957–38969. DOI: https://doi.org/10.1074/JBC.M112.357863.
Extracellular proteolysis by matrix metalloproteinase‑9 drives dendritic spine enlargement and long-term potentiation coordinately / X.-b. Wang, O. Bozdagi, J. S. Nikitczuk [et al.] // The Proceedings of the National Academy of Sciences. 2008. Vol. 105, Iss. 49. P. 19520–19525. DOI: https://doi.org/10.1073/pnas.0807248105.
The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases / G. A. Cabral-Pacheco, I. Garza-Veloz, C. Castruita-De la Rosa [et al.] // International Journal of Molecular Sciences. 2020. Vol. 21, Iss. 24. P. 9739. DOI: https://doi.org/10.3390/ijms21249739.
Li X., Jin L., Tan Y. Different roles of matrix metalloproteinase 2 in osteolysis of skeletal dysplasia and bone metastasis (Review) // Molecular Medicine Reports. 2021. Vol. 23, Iss. 1. P. 1–9. DOI: https://doi.org/10.3892/MMR.2020.11708.
Critical roles for collagenase‑3 (Mmp13) in development of growth plate cartilage and in endochondral ossification / M. Inada, Y. Wang, M. H. Byrne [et al.] // The Proceedings of the National Academy of Sciences. 2004. Vol. 101, Iss. 49. P. 17192–17197. DOI: https://doi.org/10.1073/pnas.0407788101.
Mutation of membrane type‑1 metalloproteinase, MT1‑MMP, causes the multicentric osteolysis and arthritis disease Winchester syndrome / B. R. Evans, R. A. Mosig, M. Lobl [et al.] // The American Journal of Human Genetics. 2012. Vol. 91, Iss. 3. P. 572–576. DOI: https://doi.org/10.1016/J.AJHG.2012.07.022.
Тюрин, А. В., Давлетшин Р. А., Муратова Р. М. Роль фенотипов дисплазии соединительной ткани в оценке риска развития соматической патологии // Казанский медицинский журнал. 2014. Т. 95, № 4. С. 501–505. URL: https://clck.ru/34uFgH (дата обращения: 26.06.2023).
Разин В. А., Гимаев Р. Х. Миокардиальный фиброз в артериальной гипертензии // Ульяновский медико-биологический журнал. 2013. № 3. С. 7–14. URL: https://clck.ru/34uFko (дата обращения: 26.06.2023).
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright © 2023 Shambatov M. A., Izmozherova N. V., Popov A. A., Bazarnyj V. V., Polushina L. G., Kopenkin M. A.